Imago BioSciences, Inc. (IMGO)

RAHWAY, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago BioSciences, Inc. (Nasdaq: IMGO), at a purchase price of $36.00 per share in cash, without interest and subject to deduction for any required tax withholding. As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on January 10, 2023, 31,307,028 shares of common stock of Imago were validly tendered and not withdrawn from the tender offer, representing approximately 89.2% of the total number of Imago's outstanding shares on a fully diluted basis. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for such shares.

Investing in small-cap stocks is usually a very risky business, but they could offer quick and hefty returns.

RAHWAY, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Imago BioSciences, Inc. (Nasdaq: IMGO). On Nov. 21, 2022, Merck announced that it had entered into a definitive agreement to acquire Imago.

Imago BioSciences becomes part of the Merck & Co., Inc. family for $1.35 billion. Imago BioSciences, Inc. will certainly strengthen Merck's position in hematology.

NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Imago BioSciences, Inc. (NasdaqGS: IMGO) to Merck (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Imago will receive only $36.00 in cash for each share of Imago that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Imago BioSciences (IMGO) to be acquired by pharma-giant Merck (MRK) for $1.35 billion. The transaction is likely to close by first-quarter 2023.

NEW YORK , Nov. 21, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Imago BioSciences, Inc. ("Imago" or the "Company") (NASDAQ: IMGO), in connection with the tender offer for the Company by a subsidiary of Merck & Co., Inc. (NYSE: MRK). Under the tender offer terms, the Company's shareholders will receive $36.00 in cash for each share of Imago common stock owned.

Biotech stock Imago BioSciences broke out and hit a record high Monday after Merck pledged to buy it for $1.35 billion. The post Imago BioSciences Catapults To Record High On Merck's $1.35 Billion Buyout appeared first on Investor's Business Daily.

Merck & Co., Inc. (NYSE:MRK) is set to acquire biopharmaceutical company Imago Biosciences Inc (NASDAQ:IMGO) in a cash deal worth $1.35 billion.

Merck (NYSE: MRK) announced it is buying Imago BioSciences (IMGO) for $1.35 billion. These are the details.

Merck will pay $36 in cash for each share of Imago BioSciences.

Shares of Imago BioSciences Inc. IMGO, -3.87% soared toward an eight-month high in premarket trading Monday, after the biopharmaceutical company developing treatments for myeloproliferative neoplasms (MPNs) and other bone marrow diseases announced an agreement to be acquired by Merck & Co. Inc. MRK, +1.88% in a cash deal with a equity value of $1.35 billion. Under terms of the deal, Merck will pay $36.00 for each Imago share, which represents a 106.9% premium to Friday's closing price of $17.40.

RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion.

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that Hugh Young Rienhoff, Jr., MD, CEO of Imago BioSciences, will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12 - 14, 2022.

SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ​Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Young Rienhoff, Jr., M.D., Imago's Chief Executive Officer, will participate in three upcoming investor conferences.

Imago BioSciences (IMGO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.